OpenAI has moved into scientific AI with GPT-Rosalind, a frontier reasoning model purpose-built for life sciences research. The model is designed to accelerate drug discovery pipelines, genomics analysis, protein structure reasoning, and broader scientific workflows. The release comes as Novo Nordisk announced full integration of OpenAI across its entire drug development and manufacturing operations, and as Profluent closed a $2.25B partnership with Eli Lilly for AI-designed gene therapeutics. AI in drug discovery is no longer optional — and GPT-Rosalind is OpenAI’s bid to own that category.
Keywords: GPT-Rosalind, OpenAI drug discovery, AI genomics 2026, AI life sciences, AI pharmaceutical research